Moderna CEO Stephane Bancel has sold $408 million in company stock since the start of the coronavirus pandemic, during which the firm’s share price soared more than 600% while it developed and rolled out its vaccine. The Cambridge, Massachusetts-based biotech firm developed the second-most popular vaccine used to combat COVID-19 in the United States. The shot jointly developed by Pfizer and BioNTech is the most widely used vaccine in the US. Since January 2020, Bancel cashed out stock options through the 10b5-1 plan which allows executives to sell a predetermined number of shares at regular intervals to avoid the possibility...